Drug Central

Drug results: 10

ripasudil	Rho-associated kinase inhibitor for the treatment of glaucoma and ocular hypertension
ruboxistaurin	inhibits protein kinase C beta
axitinib	A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.
baricitinib	Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulates these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs. FDA issued an Emergency use authorization (EUA) on November 19, 2020 that permits use of baricitinib in combination with remdesivir for treatment of suspected or laboratory-confirmed COVID-19 in hospitalized patients ≥2 years of age requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
bosutinib	a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases
nintedanib
fostamatinib	Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). The major metabolite of fostamatinib, R406, inhibits signal transduction of Fc-activating receptors and B-cell receptor. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets.
midostaurin	Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type and D816V mutant), PDGFR-alfa/beta, VEGFR2, as well as members of the serine/threonine kinase PKC (protein kinase C) family. Midostaurin demonstrated the ability to inhibit FLT3 receptor signaling and cell proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD mutant FLT3 receptors or overexpressing wild type FLT3 and PDGF receptors. Midostaurin also demonstrated the ability to inhibit KIT signaling, cell proliferation and histamine release and induce apoptosis in mast cells.
tofacitinib	Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.
sunitinib	An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.

Featured News

Drugcentral 2023 NAR Article

The Latest in Chemistry in Coronavirus Research

Drugs in the News

Makena Venetoclax Dapagliflozin KEYTRUDA Sacubitril LORBRENA Hydroxychloroquine

DrugCentral Search Overview

Drug search example:

Generic drug names, drug synonyms, trade names terms can be used to search for drugs. Example search for Lipitor can query using either “Atorvastatin” or “Lipitor”.A comprehensive list of drug development codes and salt or ester forms are also stored in the database and can be used as search terms, for example search for "rosuvastatin" the following terms can be used: "rosuvastatin calcium" or "ZD4522".

Disease search example:

Supported disease terms are SNOMED-CT and OMOP vocabulary terms. Disease annotations for drugs approved before 2012 originate from OMOP vocabulary mappings. For drugs approved after 2012 disease annotations are extracted manually from approved drug labels and mapped to SNOMED-CT concepts.

Example search for “Chronic Hepatitis C” returns the list of antiviral drugs indicated to treat “Chronic Hepatitis C” followed by drugs contra-indicated in hepatitis C.

New! Medical (off label) uses suggestion form
Off label Uses Form
New! Substructure Search:
The current update supports chemical substructure searching. Typing a SMILES string in the DrugCentral Substructure search bar launches a chemical substructure search that finds matching compounds in DrugCentral. E.g., N1cnccc1 . SMILES strings can be located on all Drug Cards under "Description".

New! FDA Adverse Event Reporting System:
The 2021 DrugCentral update, we separately calculated FAERS for men and women to enable research on sex differences in drug safety. The 2022 version goes further by computing adverse drug event scores granulated by age: pediatric data (FAERS_PED) covers patients from 1 day to 17 years, and geriatric data (FAERS_GER) focuses on elderly patients over 65 years of age, respectively. Female, Male, Geriatric & Pediatrics. E.g., amfetamine

New! Target Cards:
To perform a target card search enter a Uniprot target Accession ID e.g., P23975. The target cards depict the "Accession", "Swissprot", "Organism", "Gene" & "Target class" followed by "Drug relations" where the drugs "Bioactivity mechanism-of-actions" are identified.

Target search example:
Supported target search terms are HUGO gene symbols, Uniprot accessions and target names, and Swissprot identifiers. Example search for drugs targeting Mu-type opioid receptor can be run using either of the terms: “OPRM1”, P35372, “OPRM_HUMAN”, full or partial Uniprot target name. Returned drugs are ranked using the following criteria: top ranked drugs have mechanism of action target Mu-type opioid receptor, next in the list are drugs with potencies measured against this receptor.

In collaboration with the IDG
New! Veterinary Drugs, Uses & Products:

Drug Central now contains Veterinary Drugs, Uses & Products. The current update adds 1805 bioactivities for 226 veterinary drugs and 804 targets. DrugCentral veterinary data contains application numbers and types, trade names, applicant names, and prescription types for 1492 drug products as referenced in FDA’s Green Book. DrugCentral currently holds 1664 indications (pairs of drug and concept names) for 34 species. Dogs, cattle, and cats sum up to 63% of the indications covered by 193 veterinary drugs. Veterinary Drug Use can be found on each drug card by selecting the sub menu link: 🐶 Veterinary Use on the drug card. E.g., enrofloxacin
Pharmacologic action search example:

Supported pharmacologic action terms are MeSH, FDA [EPC, MoA, PE], ChEBI action roles.

Example search for “HMG-CoA Reductase Inhibitor” FDA EPC term for statin drugs returns list of all statin drugs classified by FDA as HMG-CoA reductase inhibitors.

Ranked result list is annotated with 4 level ranking system ordered from highest to lowest:

A - query term matched drug name or synonyms, mechanism of action target, or drug indication.

B - query term matched disease term in drug contraindications or off-label uses, targets listed in drug bioactivity profiles (not MoA targets), or pharmacologic action descriptions.

C - query term matched short drug description text.

D - query term matched full text in FDA drug labels.

Citing DrugCentral © 2025. License